BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 14.4//EN
BEGIN:VTIMEZONE
TZID:Central Standard Time
BEGIN:STANDARD
DTSTART:20251102T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11
TZNAME:Central Standard Time
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250301T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3
TZNAME:Central Daylight Time
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:&nbsp\;Introduction - Kelsey OverbergENDCOV-I Study Rationale &
 amp\; Design (Boehringer Ingelheim) - Nina Patel\, MDHelping the World to 
 Breathe (Three Lakes Foundation) - University of MichiganZEPHYRUS Phase 3 
 IPF Development Program (FibroGen) - Will Chou\, MD
DTEND:20211109T190000Z
DTSTAMP:20260312T021622Z
DTSTART:20211109T180000Z
LOCATION:
SEQUENCE:0
SUMMARY:Clinical Trials Innovation Series
UID:RFCALITEM639088605821965658
X-ALT-DESC;FMTTYPE=text/html:<p>&nbsp\;</p><ul><li>Introduction -<em> Kelse
 y Overberg</em></li><li>ENDCOV-I Study Rationale &amp\; Design (Boehringer
  Ingelheim) - <em>Nina Patel\, MD</em></li><li><em></em>Helping the World 
 to Breathe (Three Lakes Foundation) - <em>University of Michigan</em></li>
 <li>ZEPHYRUS Phase 3 IPF Development Program (FibroGen) - <em>Will Chou\, 
 MD</em><br></li></ul>
END:VEVENT
END:VCALENDAR